OncoMatch

OncoMatch/Clinical Trials/NCT07630961

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

Is NCT07630961 recruiting? Yes, currently enrolling (Jul 2026). This Phase 1 trial studies multiple treatments including 68Ga-DFC413 and 68Ga-NNS309 for metastatic pancreatic ductal adenocarcinoma (pdac).

Phase 1RecruitingNovartis PharmaceuticalsNCT07630961Data as of Jul 2026

Treatment: 68Ga-DFC413 · 68Ga-NNS309The purpose of Part 1 of this study is to evaluate the imaging characteristics, safety, biodistribution and pharmacokinetics of \[68Ga\]Ga-DFC413, and in Part 2 compare to \[68Ga\]Ga-NNS309 in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC), colorectal cancer (CRC), and soft tissue sarcoma (STS). In Part 2 of this study (comparison of \[68Ga\]Ga-DFC413 and \[68Ga\]Ga-NNS309), not all indications might be explored.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

68Ga-DFC41368Ga-NNS309

Cancer type

Pancreatic Cancer

Non-Small Cell Lung Carcinoma

Triple-Negative Breast Cancer

Breast Carcinoma

Colorectal Cancer

Sarcoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Lab requirements

Blood counts

ANC ≥ 1.0 x 10^9/L; Hemoglobin ≥ 9 g/dL; Platelet count ≥ 75 x 10^9/L

Kidney function

eGFR ≥ 60 mL/min (CKD-EPI 2021 or 24-hour urine)

Liver function

Total bilirubin ≤ 1.5 x ULN (except Gilbert's syndrome ≤ 3.0 x ULN); direct bilirubin ≤ 1.5 x ULN; ALT ≤ 3.0 x ULN (≤ 5.0 x ULN with liver involvement); AST ≤ 3.0 x ULN (≤ 5.0 x ULN with liver involvement)

Out-of-range laboratory values defined as: eGFR < 60 mL/min; Total bilirubin > 1.5 x ULN (except Gilbert's syndrome > 3.0 x ULN); direct bilirubin > 1.5 x ULN; ALT > 3.0 x ULN (except with liver involvement > 5.0 x ULN); AST > 3.0 x ULN (except with liver involvement > 5.0 x ULN); ANC < 1.0 x 10^9/L; Hemoglobin < 9 g/dL; Platelet count < 75 x 10^9/L

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07630961 currently recruiting?

Yes, this trial is currently recruiting patients.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify